Sony (SNE) to Report Q1 Earnings: What's in the Offing?
Sony Corporation SNE is set to report first-quarter fiscal 2018 results on Jul 31.
In the last reported quarter, the company incurred loss per share of 12 cents. Notably, Sony has exceeded estimates thrice in the trailing four quarters, delivering an average positive surprise of 49.23%.
Let’s see how things are shaping up for this announcement.
Factors to Consider
Sony’s battery business has been showing signs of weakness, and its camera module business is likely to deteriorate in the near future. Also, high costs in relation to the transfer of the battery business is weighing on the company’s financials. In addition, Mobile Communications sales decreased 1.9% year on year during the fourth-quarter fiscal 2017. The downturn was due to decline in unit sales of smartphones and increase in the price of key components. The company has also lowered its forecast for annual smartphone unit sales by 12% from its previous forecast. Intensifying competition in the smartphones domain is further weighing on its profitability.
The company has a strong international presence with majority of revenues coming from emerging markets. Of late, it has been suffering from negative impact of foreign currency fluctuations. Fluctuations in foreign exchange rates, particularly yen, the U.S. dollar and euro, impact Sony’s financials as it has significant exposure in these currencies, both in terms of sales or production costs. As many segments of the company have concentrated operations in specific regions, the currency impact differs from segment to segment. We believe that currency headwinds will remain a major drag on its financials.
Further, Sony’s financial services are subject to volatility in the world financial markets and intense competition arising from shifting customer preference toward life insurance. In addition, though Sony’s business restructuring initiatives pave way for enhancement of profitability and shareholders’ value in the long run, these also increase restructuring charges in the near term.
Further, the company faces intense rivalry in each of product lines including television, game platform and smartphone and services across the world. Failure to create new products that are in sync with customer demand may reduce sales of the company’s products. Each of these markets witnesses stiff price wars, continuous product innovations and changing customer preferences. To hedge the competitive pressure, the company needs to come up with innovative products that might lead to escalated costs in the near term.
Our proven model does not conclusively show an earnings beat for Sony in the to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Sony has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $1.11. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Sony Corporation Price and EPS Surprise
Sony Corporation Price and EPS Surprise | Sony Corporation Quote
Zacks Rank: Sony currently carries a Zacks Rank #5 (Strong Sell), which along with its ESP of 0.00% makes surprise prediction difficult.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some companies that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
AMC Networks Inc. AMCX has an Earnings ESP of +0.43% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Extended Stay America, Inc. STAY has an Earnings ESP of +4.24% and a Zacks Rank #2.
PVH Corp. PVH has an Earnings ESP of +0.08% and a Zacks Rank of 3.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sony Corporation (SNE) : Free Stock Analysis Report
AMC Networks Inc. (AMCX) : Free Stock Analysis Report
Extended Stay America, Inc. (STAY) : Free Stock Analysis Report
PVH Corp. (PVH) : Free Stock Analysis Report
To read this article on Zacks.com click here.